REPORT SCOPE
INTRODUCTION
STUDY GOALS AND OBJECTIVES
BCC’s goal for this study was to determine the status of current and emerging biochip technologies and products and assess their worldwide growth potential over a 5-year period from 2011 to 2016. We were particularly interested in characterizing the biochip markets by type (DNA microarray, protein microarray, emerging microarray, lab-on-a-chip); by function (gene expression, genotyping, micro-RNA, epigenetic, sequence capture); and by end user research and development ((R&D) tools, drug discovery, and development, diagnostics, sequencing, applied).
A particular focus of this study is the market for biochip-based diagnostics products, which highlights a major future market segment for biochips.
Our key objective was to present a comprehensive discussion of the main commercial biochip technologies and the current and future commercial potential for each of the key market segments.
REASONS FOR DOING THE STUDY
BCC previously examined the biochips industry in 2009. Since 2009, numerous industry alliances and acquisitions have occurred, which alters the competitive dynamics. In addition, more biochips-based diagnostics have been launched, as well as next-generation sequencing systems. At the same time, several market segments have been affected by a slowdown in the genome-wide association market. Given the changing industry dynamics and market shifts occurring in this industry, it is timely to re-examine the biochips business.
It is important to keep abreast of the main biochips platforms: DNA microarrays, protein microarrays, and lab-on-a-chip. DNA microarrays are an established technology generating substantial revenue derived from gene expression, genotyping, epigenetic, and micro-RNA applications. Protein microarrays are gaining prominence in the marketplace, while future, emerging array technologies, including tissue/cell and glycomics arrays are increasing in importance. Lab-on-chip devices are also making rapid progress in important pharmaceutical and diagnostics market segments.
This report is intended to guide companies in these industries about the important trends in biochips as well as provide detailed information about the individual market segments and industry dynamics.
INTENDED AUDIENCE
BCC has compiled a study of critical biochip technologies that are used in the five major end-user segments: research tools; drug discovery and development; diagnostics; sequencing; and applied markets. The report discusses the biochip platforms, market growth driving forces, product types, key market applications, companies and alliances, industry dynamics, patents, future market potential, and product sales forecasts for the period 2011 through 2016.
This study will be of particular interest to the companies in the following industries: diagnostics, pharmaceuticals, biotechnology, nanotechnology, life sciences tools, biodefense, medical devices, polymers, glass, bioinformatics, and genetic services. It will also be of interest to companies involved in drug and/or biomarker discovery programs; manufacturers of microarrays and lab-on-a-chip devices, antibodies, restriction enzymes, or primers; bioinformatics developers; and cancer researchers and clinicians.
SCOPE AND FORMAT OF REPORT
The study scope includes the major biochip platforms that are likely to become commercialized within the next 5 years. Each technology is analyzed to determine its market status, impact on future market segments, and forecasted growth from 2011 through 2016. Technology status and market driving forces are discussed. Factors that influence the market are discussed, including growth driving forces; industry alliances and acquisitions; applications in diagnostics and drug discovery; customer needs; and competitive trends.
BCC also examines specific market segments, including digital polymerase chain reaction (PCR); China biochips; and peptide microarrays. We also examine patent strategies within the industry. 140 companies are profiled in the report.
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this study. BCC examines each of the key end-user market segments that will be commercially important during the next five years: research tools; drug discovery and development; diagnostics; next-generation DNA sequencing; and applied markets (biodefense, food safety, ag-bio).
Based on this analysis, we evaluate the potential applications of biochips in each of the major market segments, and forecast sales revenues for 2011 through 2016.
For research tools and drug discovery and development, the study presents a forecast from 2011 through 2016 for each of the important products and technologies. For DNA microarrays, the study forecasts market size by application and analysis type. For diagnostics, the report forecasts from 2011 through 2016 the demand for biochips by chip type and by indication, as well as cancer biochips by type and application. This study forecasts from 2011 through 2016 the market for lab-on-a-chip (LOAC) devices by end-use market and by application. The geographical markets are forecast for each biochip type.
INFORMATION SOURCES
BCC surveyed life science companies and research institutions to obtain data for this study. Included were research tools firms, diagnostics firms, drug firms, microarray and lab-on-a-chip companies, and leading microarray research institutions. We also spoke with users of in-vitro personalized medicine devices. In addition, we compiled data from secondary sources, including industry, trade, and government.
ANALYST'S CREDENTIALS
The author, John Bergin, has written previous BCC biotechnology reports titled Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics; Global Biochip Markets: Microarrays and Lab-on-a-chip; RNA Interference in the Post-Genomics Era: Markets and Technologies; DNA Sequencing: Emerging Technologies and Markets; Biologic Imaging Reagents: Future Technologies and Markets; and Synthetic Biology. Mr. Bergin has held business development, sales, and marketing positions with a Fortune 500 advanced materials company, as well as executive management positions with an emerging nanotechnology company. Mr. Bergin holds the following degrees: BS Chemistry, MS Biotechnology, and Masters of Business Administration.
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
- Examine BCC’s complete catalog of Market Research Reports and place direct orders
- Subscribe to any of BCC’s many industry newsletters
- Read announcements of recently published reports and newly launched newsletters
- Register for BCC’s well-known conferences
- Request additional information on any BCC product
- Take advantage of special offers
DISCLAIMER
The information developed in this report, is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is of a speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or from its use.
